Teva Pharmaceutical Industries Generics Company Intelligence Report

Summary

Teva is the largest generic pharmaceutical manufacturer in the world, with sales worth US$9.4 billion in 2007. The company is Israeli-owned and headquartered, although around 60% of revenues are gained in the USA.

In July 2005, Teva announced a merger with IVAX, one of the USA's leading generic companies. The acquisition was completed in January 2006, in a deal worth some US$7.4 billion. The deal strengthened Teva's position in the USA and Latin America.

The IVAX purchase followed a previous major deal. In November 2003, Teva announced the purchase of the US manufacturer, Sicor, for US$3.4 billion. This was the largest deal in the generic drug industry at the time. It gave Teva access to Sicor's generic injectable products and biosimilar development capacity.

In 2008, Teva announced it was acquiring the US generic firm, Bentley Pharmaceuticals, in a deal worth some US$360 million. Although based in the US, Bentley's main business was in Spain, with additional operations in other parts of Europe.

In July 2008, Teva Pharmaceutical Industries announced plans to acquire Barr in a deal worth some US$7.46 billion. Should the deal go through, the new company would operate in over 60 countries and employ some 37,000 people.

While the bulk of Teva's revenues are derived from generics, the company has one major innovative product, Copaxone. This is a treatment for multiple sclerosis. Sales of Copaxone broke the US$1 billion mark in 2005. A second innovative product, Azilect (rasagiline, Parkinson's disease), was launched in 2006. Teva is also involved in research in other areas such as drug delivery and biosimilars.Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Contents

• Executive Summary
• Introduction
• Products
  • Teva Anda Approvals 2002-08
  • Ivax Anda Approvals, 2002-07
  • Gensia Sicor Pharmaceuticals / Sicor Anda Approvals, 2003-07
  • Pharmachemie Anda Approvals, 2003-07
  • Novopharm Anda Approvals, 2003-04
  • Goldline Laboratories / Zenith Goldline Anda Approvals, 2002-05
  • Recent Product Approvals
  • Teva Receives Fda Approval for Generic Risperdal Tablets
  • Valsartan (Ivax, Tentative)
  • Teva Begins Shipping Bupropion Tablets
  • Teva Gains Fda Approval of Generic Sarafem Pulvules
  • Epoprostenol
  • Rizatriptan (Tentative)
  • Raloxifene (Tentative)
  • Irinotecan Hydrochloride
  • G-Csf Biosimilar from Teva Receives Positive Chmp Opinion
  • Alendronate
  • Tamsulosin (Tentative)
  • Lansoprazole (Tentative)
  • Pravastatin
  • Donepezil (Tentative)
  • Sumatriptan (UK)
  • Ceftriaxone
  • Pantoprazole
  • Ipratropium Bromide + Albuterol
  • Granisetron
  • Risperidone (UK)
  • Oxcarbazepine
  • Ropinirole (Tentative)
  • Valaciclovir (Tentative)
  • Risedronate
  • Teva Gains Positive Olanzapine Opinion
  • Carvedilol
• Teva
• Generic Companies Analysis
  • Sildenafil (Tentative)
  • Epirubicin Injection
  • Fosphenytoin
  • Terbinafine
• Financial Results
  • Latest Full Year Results, Fiscal 2007
  • Full Year Results, 2003 - 2007 (US$ Millions)
  • Pharmaceutical Sales
  • North America
  • Europe
  • International
  • Animal Health
  • Innovative Products
  • Specialty Products
  • Active Pharmaceutical Ingredients Sales
  • Pharmaceutical Sales
  • North America
  • Europe
  • International
  • Global in-Market Sales of Copaxone and Azilect
  • Respiratory Products
  • Api Sales
• Major Developments
  • Mergers, Acquisitions and Agreements
  • Teva to Acquire Barr
  • Teva Acquires Bentley Pharmaceuticals
  • Czech Expansion
  • Irish Expansion
  • Hungarian Expansion
  • Cogenesys Acquisition
  • Ucb
  • Antares
  • UK Expansion
  • Biosante and Teva Restart Testosterone Product Development
  • Litigation
• Generic Companies Analysis
• Teva
  • Fda Review of Generic Copaxone Prompts Lawsuit from Teva
  • Summary Judgement Granted for Seroquel Patent Litigation
  • Enoxaparin
  • Escitalopram (UK)
  • Brussels Court Revokes Msd's European Alendronate Patent
  • Quetiapine
  • Celecoxib
  • Solvay Subsidiaries File Fenofibrate Suits against Teva
  • Forest and Merz File Lawsuits for Memantine Patent Infringement
  • Teva Finalises Adenosine Settlement with Astellas, King and Item
  • Teva Wins Appeal Court Ruling Concerning Cyclosporine
  • Glaxosmithkline and Teva Settle Rosiglitazone Suit
  • Novartis' Famciclovir Motion Denied; Teva Recommences Sales
  • Teva Sues Apotex over Carvedilol
  • Appeals Court Favours Pfizer over Teva in Gabapentin Case
  • Dr Reddy''s and Teva Settle Sertraline Action
  • Roche Files Complaint over Teva''s Ibandronate
  • Court Favours Teva/Sun in Pantoprazole Motion
  • Appeals Court Upholds Escitalopram Decision
  • Novartis' Motion for Preliminary Injunction against Teva's Lotrel Generics Denied
• Contact Details